CY1120062T1 - Σωστα διπλωμενη ετανερσεπτη με υψηλη καθαροτητα και εξαιρετικη αποδοση - Google Patents

Σωστα διπλωμενη ετανερσεπτη με υψηλη καθαροτητα και εξαιρετικη αποδοση

Info

Publication number
CY1120062T1
CY1120062T1 CY20181100172T CY181100172T CY1120062T1 CY 1120062 T1 CY1120062 T1 CY 1120062T1 CY 20181100172 T CY20181100172 T CY 20181100172T CY 181100172 T CY181100172 T CY 181100172T CY 1120062 T1 CY1120062 T1 CY 1120062T1
Authority
CY
Cyprus
Prior art keywords
transfer
correctly
preparations
transducer
folded
Prior art date
Application number
CY20181100172T
Other languages
English (en)
Inventor
Tsutomu Arakawa
Douglas Farrar
Original Assignee
Coherus Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50233493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120062(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences, Inc. filed Critical Coherus Biosciences, Inc.
Publication of CY1120062T1 publication Critical patent/CY1120062T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Μια μέθοδος χρωματογραφίας μικτού τύπου για το διαχωρισμό σωστά διπλωμένης ετανερσέπτης από λανθασμένα διπλωμένες διαμορφώσεις μιας δεδομένης πρωτεΐνης. Η μέθοδος είναι πολύ αποτελεσματική στο διαχωρισμό της σωστά διπλωμένης ετανερσέπτης από τη λανθασμένα διπλωμένη ετανερσέπτη και συσσωματώσεις σε εμπορικά ελκυστικές αποδόσεις ικανές να παρέχουν παρασκευάσματα ετανερσέπτης που έχουν πολύ υψηλή καθαρότητα όσον αφορά τη σωστά διπλωμένη ετανερσέπτη έναντι της λανθασμένα διπλωμένης ετανερσέτπης. Η εφεύρεση απευθύνεται περαιτέρω σε παρασκευάσματα πρωτεΐνης και σκευάσματα που περιλαμβάνουν σωστά διπλωμένες πρωτεΐνες που λαμβάνονται με χρήση των παρόντων μεθόδων, και μεθόδους θεραπείας χρησιμοποιώντας τα υψηλής καθαρότητας παρασκευάσματα που λαμβάνονται από τη μέθοδο μικτού τύπου.
CY20181100172T 2012-09-11 2018-02-13 Σωστα διπλωμενη ετανερσεπτη με υψηλη καθαροτητα και εξαιρετικη αποδοση CY1120062T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261699552P 2012-09-11 2012-09-11
PCT/US2013/058994 WO2014043103A1 (en) 2012-09-11 2013-09-10 Correctly folded etanercept in high purity and excellent yield

Publications (1)

Publication Number Publication Date
CY1120062T1 true CY1120062T1 (el) 2018-12-12

Family

ID=50233493

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100172T CY1120062T1 (el) 2012-09-11 2018-02-13 Σωστα διπλωμενη ετανερσεπτη με υψηλη καθαροτητα και εξαιρετικη αποδοση

Country Status (32)

Country Link
US (6) US20140072560A1 (el)
EP (1) EP2895188B1 (el)
JP (3) JP2015533797A (el)
KR (2) KR102133699B1 (el)
CN (2) CN110051823A (el)
AR (1) AR092532A1 (el)
AU (2) AU2013315750B9 (el)
BR (1) BR112015005161A2 (el)
CA (1) CA2882551A1 (el)
CL (1) CL2015000572A1 (el)
CO (1) CO7400876A2 (el)
CY (1) CY1120062T1 (el)
DK (1) DK2895188T3 (el)
DO (1) DOP2015000055A (el)
EA (1) EA031324B1 (el)
EC (1) ECSP15014138A (el)
ES (1) ES2657377T3 (el)
HR (1) HRP20180182T1 (el)
HU (1) HUE036524T2 (el)
IL (2) IL237311B (el)
IN (1) IN2015KN00452A (el)
LT (1) LT2895188T (el)
MX (2) MX360044B (el)
NO (1) NO2972131T3 (el)
PE (2) PE20200607A1 (el)
PL (1) PL2895188T3 (el)
PT (1) PT2895188T (el)
RS (1) RS57013B1 (el)
SG (1) SG11201501460RA (el)
SI (1) SI2895188T1 (el)
TW (2) TWI609877B (el)
WO (1) WO2014043103A1 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
WO2013059406A1 (en) 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
EP3155009A1 (en) * 2014-06-13 2017-04-19 Lupin Limited Process for the purification of tnfr:fc fusion protein
EP2975050B1 (en) * 2014-07-18 2019-05-29 Sandoz Ag Quantification of misfolded TNFR2:Fc
KR102018608B1 (ko) * 2014-12-31 2019-09-06 주식회사 엘지화학 목적하는 함량으로 불순물을 포함하는 TNFR-Fc 융합 단백질의 제조방법
EP3268042A4 (en) 2015-03-13 2018-08-01 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
JP2018538268A (ja) * 2015-11-18 2018-12-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ イオン交換クロマトグラフィーにおける改善されたタンパク質分離
CA3005484A1 (en) * 2015-11-18 2017-05-26 Merck Patent Gmbh Opposite ph-salt gradients for improved protein separations
AR108800A1 (es) * 2016-06-17 2018-09-26 Genentech Inc Purificación de anticuerpos multiespecíficos
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
JP2020511516A (ja) * 2017-03-24 2020-04-16 カウンスィル オブ サイエンティフィック アンド インダストリアル リサーチＣｏｕｎｃｉｌ Ｏｆ Ｓｃｉｅｎｔｉｆｉｃ ＆ Ｉｎｄｕｓｔｒｉａｌ Ｒｅｓｅａｒｃｈ 組換え抗体断片の精製方法
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN112876567A (zh) * 2019-11-29 2021-06-01 广东菲鹏制药股份有限公司 Fc融合蛋白及其纯化方法
AU2022236913A1 (en) * 2021-03-16 2023-10-26 Kashiv Biosciences, Llc Novel formulation of fusion protein
WO2022234412A1 (en) * 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
EP1171148A2 (en) 1999-04-19 2002-01-16 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
MXPA02007683A (es) 2000-02-10 2002-12-13 American Home Prod Metodo para tratar o inhibir la lesion celular o muerte celular.
PT1314437E (pt) 2000-08-11 2014-08-29 Chugai Pharmaceutical Co Ltd Preparações estabilizadas contendo anticorpo
SK10472003A3 (sk) 2001-02-23 2004-03-02 Immunex Corporation Zvýšený výťažok aktívnych proteínov
WO2003072060A2 (en) 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
ATE464043T1 (de) * 2002-08-22 2010-04-15 Vasopharm Biotech Gmbh Pharmazeutische zusammensetzung enthaltend l- arginin
US20040115263A1 (en) 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
ATE394123T1 (de) 2003-02-28 2008-05-15 Ares Trading Sa Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1
WO2004082715A1 (ja) 2003-03-20 2004-09-30 Eisai Co., Ltd. 炎症性腸疾患治療剤としての併用医薬
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
DK1680137T3 (da) 2003-10-14 2013-02-18 Hoffmann La Roche Makrocyklisk carboxylsyre- og acylsulfonamidforbindelse som inhibitor af HCV-replikation
US7750129B2 (en) * 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
JP5554466B2 (ja) 2004-03-01 2014-07-23 味の素株式会社 抗ヒトＴＮＦ−α抗体活性低下抑制剤
EP2540815A1 (en) 2004-03-05 2013-01-02 DSM IP Assets B.V. Perfusion cell culture
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
AU2006256041B2 (en) 2005-06-10 2012-03-29 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CN101822820A (zh) 2005-12-20 2010-09-08 布里斯托尔—迈尔斯斯奎布公司 稳定蛋白质制剂
US7390786B2 (en) 2005-12-21 2008-06-24 Wyeth Protein formulations with reduced viscosity and uses thereof
CA2638811A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
WO2007109254A2 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
EP2021030A2 (en) 2006-04-21 2009-02-11 Amgen, Inc. Buffering agents for biopharmaceutical formulations
US20080112953A1 (en) 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (en) 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
JP5577098B2 (ja) 2006-12-21 2014-08-20 アムジエン・インコーポレーテツド ポリペプチドを含有する安定な緩衝化された製剤
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
WO2008157356A2 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
NZ709704A (en) 2007-11-30 2017-03-31 Abbvie Biotechnology Ltd Protein formulations and methods of making same
MX2010009398A (es) * 2008-02-29 2010-11-12 Biogen Idec Inc Proteinas de fusion de inmunoglobulinas purificadas y los metodos para su purificacion.
EP2288617B1 (en) * 2008-06-05 2014-03-26 Affibody AB Polypeptide
WO2011015926A1 (en) 2009-08-03 2011-02-10 Avesthagen Limited A process of fermentation, purification and production of recombinant soluble tumour necrosis factor alfa receptor (tnfr) - human igg fc fusion protein
US8536316B2 (en) 2009-08-07 2013-09-17 Emd Millipore Corporation Methods for purifying a target protein from one or more impurities in a sample
EP3760712A1 (en) 2009-08-11 2021-01-06 F. Hoffmann-La Roche AG Production of proteins in glutamine-free cell culture media
EP2490780A4 (en) * 2009-10-20 2014-04-09 Merck Sharp & Dohme USE OF MIXED MODE CHROMATOGRAPHY FOR CAPTURE AND PURIFICATION OF BASIC ANTIBODY PRODUCTS
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
SG185038A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell culture medium
EP2568960B1 (en) * 2010-05-10 2018-06-06 Intas Pharmaceuticals Ltd. Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
EP2598167B1 (en) 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
AU2011296702A1 (en) 2010-08-31 2013-03-21 Friesland Brands B.V. Culture medium for eukaryotic cells
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
ES2759931T3 (es) 2011-04-20 2020-05-12 Sandoz Ag Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
JP6463968B2 (ja) * 2011-07-01 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法
CN107988166B (zh) 2011-07-01 2022-03-15 美国安进公司 哺乳动物细胞培养
DK2729482T3 (en) * 2011-07-08 2018-05-07 Merck Sharp & Dohme PROCEDURE FOR CLEANING FC-FUSION PROTEIN
KR101454316B1 (ko) * 2011-08-17 2014-10-27 한화케미칼 주식회사 활성형 ＴＮＦＲ-Ｆｃ 융합 단백질을 제조하는 방법
US10493151B2 (en) * 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
WO2013059406A1 (en) * 2011-10-18 2013-04-25 Coherus Biosciences, Inc. Etanercept formulations stabilized with metal ions
EP2869817A4 (en) * 2012-07-09 2016-04-06 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
BR112015005161A2 (pt) * 2012-09-11 2017-07-04 Coherus Biosciences Inc etanercepte corretamente dobrado em alta pureza e excelente rendimento
JP6757311B2 (ja) * 2014-07-31 2020-09-16 エムティティ イノベーション インコーポレイテッドＭｔｔ Ｉｎｎｏｖａｔｉｏｎ Ｉｎｃｏｒｐｏｒａｔｅｄ フリーフォームレンジングのための数値的アプローチ、エリアパラメータ化フリーフォームレンジング
US20160108634A1 (en) * 2014-10-16 2016-04-21 Ronald Uphold Pool Cover Hanger Device

Also Published As

Publication number Publication date
IL267452B (en) 2021-05-31
IL237311A0 (en) 2015-04-30
JP6913066B2 (ja) 2021-08-04
TWI609877B (zh) 2018-01-01
CO7400876A2 (es) 2015-09-30
TW201425331A (zh) 2014-07-01
CA2882551A1 (en) 2014-03-20
KR102133699B1 (ko) 2020-07-14
AU2013315750B2 (en) 2018-07-12
AU2018247244B2 (en) 2020-05-28
ES2657377T3 (es) 2018-03-05
WO2014043103A1 (en) 2014-03-20
HRP20180182T1 (hr) 2018-04-20
EP2895188B1 (en) 2017-11-15
KR20200085937A (ko) 2020-07-15
EA031324B1 (ru) 2018-12-28
US20190300601A1 (en) 2019-10-03
TW201803593A (zh) 2018-02-01
PE20150996A1 (es) 2015-08-01
US20140072560A1 (en) 2014-03-13
US10954293B2 (en) 2021-03-23
CN110051823A (zh) 2019-07-26
US20190300600A1 (en) 2019-10-03
MX2015003090A (es) 2015-07-14
MX2018012749A (es) 2020-11-12
JP2015533797A (ja) 2015-11-26
AU2018247244A1 (en) 2018-11-01
IL237311B (en) 2019-07-31
US11001627B2 (en) 2021-05-11
BR112015005161A2 (pt) 2017-07-04
US10947306B2 (en) 2021-03-16
PE20200607A1 (es) 2020-03-10
CN104902914B (zh) 2019-01-01
JP2021100929A (ja) 2021-07-08
AR092532A1 (es) 2015-04-22
IN2015KN00452A (el) 2015-07-17
JP2019038817A (ja) 2019-03-14
AU2013315750B9 (en) 2018-11-15
IL267452A (en) 2019-08-29
EA201590542A1 (ru) 2015-07-30
ECSP15014138A (es) 2016-01-29
US10954295B2 (en) 2021-03-23
DOP2015000055A (es) 2015-04-30
US20190330325A1 (en) 2019-10-31
US20180037642A1 (en) 2018-02-08
RS57013B1 (sr) 2018-05-31
KR20150056601A (ko) 2015-05-26
AU2013315750A1 (en) 2015-03-05
EP2895188A1 (en) 2015-07-22
CL2015000572A1 (es) 2016-02-05
US10954294B2 (en) 2021-03-23
PT2895188T (pt) 2018-02-08
CN104902914A (zh) 2015-09-09
MX360044B (es) 2018-10-19
KR102250937B1 (ko) 2021-05-12
NO2972131T3 (el) 2018-04-21
EP2895188A4 (en) 2016-05-25
DK2895188T3 (en) 2018-02-26
SG11201501460RA (en) 2015-04-29
LT2895188T (lt) 2018-04-10
PL2895188T3 (pl) 2018-06-29
HUE036524T2 (hu) 2018-07-30
TWI716649B (zh) 2021-01-21
US20190300602A1 (en) 2019-10-03
SI2895188T1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
CY1120062T1 (el) Σωστα διπλωμενη ετανερσεπτη με υψηλη καθαροτητα και εξαιρετικη αποδοση
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
CY1121934T1 (el) Αντισωματα anti-fcrn
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
CY1123403T1 (el) Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων
EA201891415A1 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
MX2016001555A (es) Modulocinas basadas en dominio sushi de interleucina-15 (il-15) y receptor alfa de interleucina-15 (il-15ra).
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
AR092050A1 (es) Proteinas de fusion de anticuerpos e interleuquina 10 y usos de las mismas
EA201791507A1 (ru) Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7
EA201391632A1 (ru) Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201790109A1 (ru) Толерогенные синтетические наноносители, уменьшающие иммунный ответ на терапевтические белки
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
EA201690529A1 (ru) Способы модификации клетки-хозяина
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
CO2020000090A2 (es) Cromatografia
BR112015024755A2 (pt) método de produção de proteína
CY1124707T1 (el) Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων)
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
EP3013960A4 (en) Modified matrix proteins of vesicular stomatitis virus
BR112018001148A2 (pt) heterômeros compreendendo proteínas de fusão com domínios de anticorpos